Shs · CUSIP 02157Q109 · who reports it, how much, and how much it matters to them
17 of the 720 hedge fund managers we track reported shares of Alto Neuroscience, Inc. (NYSE: ANRO) on Form 13F for 30 June 2026. Between them they reported USD 270m. The largest position belongs to Alpha Wave Global, at USD 98m.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Alpha Wave Global1 fund on PPLI.com | USD 98m | 1.6% |
| 2 | Perceptive Advisors6 funds on PPLI.com | USD 42m | 0.6% |
| 3 | Adage Capital Management1 fund on PPLI.com | USD 42m | 0.1% |
| 4 | Armistice Capital1 fund on PPLI.com | USD 23m | 0.3% |
| 5 | Millennium Management6 funds on PPLI.com | USD 15m | 0.0% |
| 6 | POINT72 Asset Management17 funds on PPLI.com | USD 13m | 0.0% |
| 7 | Orbimed Advisors1 fund on PPLI.com | USD 6.8m | 0.1% |
| 8 | Schonfeld Strategic Advisors30 funds on PPLI.com | USD 6.8m | 0.0% |
| 9 | Marshall Wace LLP84 funds on PPLI.com | USD 6m | 0.0% |
| 10 | Two Sigma Investments35 funds on PPLI.com | USD 3.9m | 0.0% |
| 11 | Eversept Partners3 funds on PPLI.com | USD 3.4m | 0.2% |
| 12 | Boothbay Fund Management2 funds on PPLI.com | USD 2.8m | 0.0% |
| 13 | Alkeon Capital Management19 funds on PPLI.com | USD 2.7m | 0.0% |
| 14 | Awm Investment Company6 funds on PPLI.com | USD 2.1m | 0.2% |
| 15 | Renaissance Technologies13 funds on PPLI.com | USD 1.9m | 0.0% |
| 16 | Squarepoint Ops7 funds on PPLI.com | USD 562,000 | 0.0% |
| 17 | Persistent Asset Partners10 funds on PPLI.com | USD 203,000 | 0.1% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Alpha Wave Global | USD 98m | 1.6% |
| 2 | Perceptive Advisors | USD 42m | 0.6% |
| 3 | Armistice Capital | USD 23m | 0.3% |
| 4 | Awm Investment Company | USD 2.1m | 0.2% |
| 5 | Eversept Partners | USD 3.4m | 0.2% |
| 6 | Orbimed Advisors | USD 6.8m | 0.1% |
| 7 | Persistent Asset Partners | USD 203,000 | 0.1% |
| 8 | Adage Capital Management | USD 42m | 0.1% |
| 9 | Boothbay Fund Management | USD 2.8m | 0.0% |
| 10 | Schonfeld Strategic Advisors | USD 6.8m | 0.0% |
Alto Neuroscience, Inc. trades under the symbol ANRO on the New York Stock Exchange. Its CUSIP, the code used on Form 13F, is 02157Q109.
17 of the 720 hedge fund managers PPLI.com tracks reported Alto Neuroscience, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Alpha Wave Global (USD 98m), Perceptive Advisors (USD 42m), Adage Capital Management (USD 42m), Armistice Capital (USD 23m) and Millennium Management (USD 15m).
17 managers in our coverage reported it, and between them they run 242 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Alpha Wave Global, where the position was 1.6% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Alto Neuroscience, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.